Magnetar Financial LLC Invests $2.56 Million in Atrion Co. (NASDAQ:ATRI)

Magnetar Financial LLC bought a new stake in shares of Atrion Co. (NASDAQ:ATRI) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,668 shares of the medical instruments supplier’s stock, valued at approximately $2,564,000. Magnetar Financial LLC owned about 0.32% of Atrion as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in ATRI. Kayne Anderson Rudnick Investment Management LLC lifted its position in Atrion by 1.0% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,393 shares of the medical instruments supplier’s stock valued at $92,926,000 after purchasing an additional 2,111 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Atrion by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock worth $39,344,000 after buying an additional 326 shares during the period. Bank of New York Mellon Corp grew its position in shares of Atrion by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock worth $6,751,000 after buying an additional 436 shares during the last quarter. Versor Investments LP purchased a new position in shares of Atrion during the second quarter valued at approximately $3,247,000. Finally, Penn Mutual Asset Management LLC bought a new position in shares of Atrion during the fourth quarter valued at approximately $1,949,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Atrion Price Performance

Shares of NASDAQ ATRI opened at $459.92 on Tuesday. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $503.24. The stock has a market capitalization of $809.46 million, a P/E ratio of 43.23 and a beta of 0.69. The company’s 50-day moving average is $459.06 and its 200 day moving average is $446.19.

Atrion (NASDAQ:ATRI) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. The firm had revenue of $48.77 million for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Atrion in a report on Thursday, September 19th. They issued a “sell” rating on the stock.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.